Unjha Formulations Limited (BOM:531762)
24.79
+0.05 (0.20%)
At close: Jul 28, 2026
Unjha Formulations Revenue
In the fiscal year ending March 31, 2026, Unjha Formulations had annual revenue of 155.85M INR with 11.89% growth. Unjha Formulations had revenue of 31.65M in the quarter ending March 31, 2026, with 32.31% growth.
Revenue
155.85M
Revenue Growth
+11.89%
P/S Ratio
0.71
Revenue / Employee
10.39M
Employees
15
Market Cap
111.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 155.85M | 16.56M | 11.89% |
| Mar 31, 2025 | 139.30M | -45.66M | -24.69% |
| Mar 31, 2024 | 184.96M | 53.42M | 40.61% |
| Mar 31, 2023 | 131.54M | -10.24M | -7.22% |
| Mar 31, 2022 | 141.77M | 42.16M | 42.32% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 1.16B |
| Beryl Drugs | 188.20M |
| Brawn Biotech | 169.78M |
| Zenith Healthcare | 105.22M |
| Norris Medicines | 81.32M |
| Desh Rakshak Aushdhalaya | 71.04M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 24.07M |